Human antibodies specific to KDR and uses thereof

Details Human antibodies specific to KDR and uses thereof Human antibodies specific to KDR and uses thereof

2008-09-19

2011-11-15

Goddard, Laura B (Department: 1643)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C530S387100

Reexamination Certificate

active

08057791

ABSTRACT:
The invention provides an antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralizes activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, and single domain antibodies. The invention further provides nucleic acids and host cells that encode and express these antibodies. The invention further provides a method of neutralizing the activation of KDR, a method of inhibiting angiogenesis in a mammal and a method of inhibiting tumor growth in a mammal.

REFERENCES:
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 2003/0108545 (2003-06-01), Rockwell et al.
patent: 02/070008 (2002-09-01), None
patent: 03/002144 (2003-01-01), None
Lu et al. (Int. J. Cancer Jan. 2002 vol. 97, p. 393-399).
Henk et al. (Clinical Breast Cancer, vol. 1, Suppl. 1, S80-84, Sep. 2000).
Brekken et al. Cancer Research. vol. 60, p. 5117-5124, Sep. 15, 2000.
Lu, et al., “Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy.”, bit. J. Cancer, Jan. 2002. vol. 97, pp. 393-399.
Shaheen, R. M., et al.: “Inhibited Growth of Colon Cancer Carcinomatosis by Antibodies to Vascular Endothelial and Epidermal Growth Factor Receptors”, British J. Cancer, London, GB, Aug. 2001, 85(4):584-589.
Marks, J.D., et al.: “By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling” Bio/Technol., Nature Pub. Co., N.Y., US, Jul. 1992, 10(7):779-783.
Hoogenboom, H.R., et al.: “Natural and Designer Binding Sites Made By Phage Display Technology” Immunol. Today, Elsevier Pub., Cambridge, GB, Aug. 2000, 21(8):371-378.
Lu, et al., J. Biological Chemistry 278(14):43496-43507 (2003).

Affiliated with

Also associated with

Rating

Human antibodies specific to KDR and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human antibodies specific to KDR and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human antibodies specific to KDR and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4283648